Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-11-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于子公司向银行申请综合授信额度并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a listed company regarding its subsidiary applying for a comprehensive credit facility from banks and providing guarantees. It includes details about the credit limits, guarantees, financial data of the subsidiaries, board resolutions, and the need for shareholder approval. The document is a formal announcement of a financing and guarantee arrangement, not a full financial report or earnings release. It does not contain comprehensive financial statements or detailed management discussion but focuses on capital/financing updates related to credit facilities and guarantees. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3556 characters, which is typical for an announcement rather than a full report. No indication of it being a regulatory filing or report publication announcement is found, and it is not a certification or legal proceeding report.
2025-11-24 Chinese
公司章程（2025年11月）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for Sailong Pharmaceutical Group Co., Ltd. It includes chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the charter, and other corporate governance matters. The content is legal and governance-related, focusing on the company's internal rules, shareholder rights, board structure, meeting procedures, and management responsibilities. There is no indication of financial statements, audit opinions, earnings data, or investor presentations. The document is not an announcement or a brief notice but a comprehensive governance document. Therefore, the most appropriate classification is Governance Information (CGR).
2025-11-24 Chinese
第四届董事会独立董事2025年第三次专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the independent directors of the board regarding a specific agenda item about a subsidiary applying for a bank credit facility and providing guarantees. It references relevant laws and regulations and concludes with the independent directors' approval to submit the proposal to the board meeting. The document is short (733 characters) and does not contain financial statements or detailed financial data. It is a board/management related announcement about a governance matter, specifically the independent directors' review and opinion on a board agenda item. Therefore, it fits best under Board/Management Information (MANG).
2025-11-24 Chinese
关于召开2025年第四次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 fourth extraordinary general meeting (临时股东会) of shareholders for 赛隆药业集团股份有限公司. It includes information about the meeting date, location, agenda items to be voted on, voting procedures (including online voting), registration details, and proxy authorization forms. There are no financial statements or financial performance data included. The document is not an annual or interim report, earnings release, or any financial report. It is a formal announcement notifying shareholders about the meeting and providing instructions for participation and voting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is under 5,000 characters, but it contains substantive meeting and voting information, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is PSI with high confidence.
2025-11-24 Chinese
第四届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 4th Board of Directors of the company. It includes details about the meeting date, attendance, agenda items, voting results, and references to related announcements for shareholder meetings and other corporate actions. The content focuses on board decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial statements or detailed management discussion. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-11-24 Chinese
关于证券事务代表辞职的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement regarding the resignation of a securities affairs representative from the company. It includes details about the resignation, the individual's lack of shareholding, and the company's plan to appoint a replacement. There is no financial data, no mention of financial results, reports, or regulatory certifications. The content focuses on a change in company personnel related to securities affairs, which aligns with announcements about changes in company management or board-related roles. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2025-11-17 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.